W
WLC

Topic

regulatory-policy

2 articles on regulatory-policy in longevity medicine. View all news →

Victoria Department of Health retatrutide health alert Peer-reviewed

Retatrutide Safety Alert: What Longevity Clinic Buyers Should Know About Unapproved Peptides

Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.

peptide-therapy GLP-1 longevity clinic metabolic health
NPR: The government may soon lift restrictions on some peptide treatments Peer-reviewed

FDA Peptide Reclassification 2026: What It Means for Longevity Clinics and Patients

HHS Secretary Kennedy announced ~14 peptides will move from Category 2 (restricted) to Category 1 (legal for compounding). Here's what the reclassification means for longevity medicine, which peptides are returning, and why physician oversight matters more than ever.

peptide-therapy FDA-regulation longevity-treatments